BEDMINSTER, N.J., Oct. 18 /PRNewswire-FirstCall/ -- Bioject Medical
Technologies, Inc. (Nasdaq: BJCT), a leading developer of needle-free drug
delivery systems, today announced that the company's needle-free technology
for vaccine delivery will be used in a National Institutes of Health (NIH)-
sponsored Phase 2 clinical trial of a "prime-boost" vaccine approach against
HIV. The trial involves priming an immune response with multiple doses of a
plasmid DNA vaccine and boosting the response with a single dose of adenoviral
vector vaccine given at a later date. The trial will utilize the Company's
Biojector(R) 2000 (B2000) needle-free system exclusively for DNA vaccine
delivery.
The vaccine was developed by scientists at the Dale and Betty Bumpers
Vaccine Research Center (VRC) of the National Institute of Allergy and
Infectious Diseases (NIAID), which is part of the NIH. The new HIV vaccine
trial is the first VRC program to advance an HIV DNA vaccine into Phase 2
trials.
Commenting on the announcement, Jim O'Shea, Bioject's Chairman, President
and Chief Executive Officer stated, "We have been working with the VRC for
several years in different trials where our needle-free technology has been
successful in administering various DNA vaccines. We are very pleased that
all injections using this new DNA vaccine for HIV are being delivered with the
B2000. The progress into Phase 2 of the trial represents an important
milestone in our relationship with the NIH."
The B2000 is a CO2 powered reusable needle-free injection system, which
has FDA clearance to deliver intramuscular and subcutaneous injections of
vaccines and other medications up to 1.0 ml in volume.
Bioject Medical Technologies Inc., based in Bedminster, New Jersey, with
operations in Portland, Oregon, is an innovative developer and manufacturer of
needle-free drug delivery systems. Needle-free injection works by forcing
medication at high speed through a tiny orifice held against the skin. This
creates a fine stream of high-pressure fluid penetrating the skin and
depositing medication in the tissue beneath. The Company is focused on
development mutually beneficial agreements with leading pharmaceutical,
biotechnology and veterinary companies.
This press release contains a forward-looking statement within the meaning
of the Private Securities Litigation Reform Act of 1995 regarding the use of
the Company's B-2000 product in the NIH-sponsored clinical trial. Such
forward-looking statement involves known and unknown risks, uncertainties and
other factors that may cause the actual performance or achievements of the
Company to be materially different from any future performance or achievements
expressed or implied by such forward-looking statement. Such risks,
uncertainties and other factors include, without limitation, the risk that the
NIH will cancel the trial the trial or elect to use a product other than the
B-2000 in the trial. Readers of this press release are referred to the
Company's filings with the Securities and Exchange Commission, including the
Company's reports on Form 10-K and Forms 10-Q for further discussions of
factors that could affect the Company's business and its future results.
Forward-looking statements are based on the estimates and opinions of
management on the date the statements are made. The Company assumes no
obligation to update forward-looking statements if conditions or management's
estimates or opinions should change.
For more information about Bioject, visit http://www.bioject.com
SOURCE Bioject Medical Technologies Inc.
 back to top
Related links:
http://www.bioject.com
CONTACT:
John Gandolfo, Chief Financial Officer of
Bioject Medical Technologies Inc., +1-908-470-2800, ext. 5102, or
jgandolfo@bioject.com; or John Baldissera of BPC Financial
Marketing, +1-800-368-1217, for Bioject Medical Technologies Inc.
|
